SANJAY GUPTA: Open Payments
NPI 1740238906 · CHEEKTOWAGA, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$379,453 in 358 payments from 10 companies in 2025. Trend: 2023 $347,227 · 2024 $271,541 · 2025 $379,453
Speaker / faculty: $318,589Travel & lodging: $35,292Consulting: $18,866Food & beverage: $6,707
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 109 | $110,559 |
| Neurocrine BioSciences, Inc. | 74 | $81,616 |
| Vanda Pharmaceuticals Inc. | 59 | $71,547 |
| Otsuka America Pharmaceutical, Inc. | 41 | $45,136 |
| E.R. Squibb & Sons, L.L.C. | 31 | $32,870 |
| Teva Pharmaceuticals USA, Inc. | 15 | $19,057 |
| Janssen Pharmaceuticals, Inc | 24 | $18,436 |
| Janssen Scientific Affairs, LLC | 1 | $131 |
| Alkermes, Inc. | 3 | $81 |
| Axsome Therapeutics, Inc. | 1 | $19 |
Products named: CAPLYTA, INGREZZA, FANAPT, REXULTI, COBENFY, UZEDY, SPRAVATO, ABILIFY MAINTENA.
Industry payments across NY — which companies pay providers there.
